Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:immunotherapy
|
| gptkbp:alsoKnownAs |
SAR444245
|
| gptkbp:amendedBy |
PEGylated IL-2 variant
|
| gptkbp:clinicalTrialPhase |
Phase 1
NCT04009681 |
| gptkbp:designedFor |
reduce toxicity compared to native IL-2
stimulate immune response against tumors |
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Synthorx |
| gptkbp:indication |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
IL-2 pathway agonist
selective IL-2Rβγ agonist |
| gptkbp:origin |
gptkb:engineered_protein
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
gptkb:investigational_drug
|
| gptkbp:target |
interleukin-2 receptor beta-gamma
|
| gptkbp:bfsParent |
gptkb:Synthorx
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
THOR-707
|